MicroConstants, a CRO specializing in regulated bioanalysis and DMPK, has appointed Doinita Serban, Ph.D., director of biomarker research to oversee the expansion of biomarker testing and analysis services for preclinical and clinical diagnostic research. Doinita's experience with biomarker assay development, validation and profiling of disease panels, coupled with the implementation of the Luminex platform, will enable MicroConstants to broaden its biomarker analysis capabilities to include additional assay formats, such as multiplex immunoassays, gene expression and profiling assays.

Doinita brings more than 15 years of experience in the pharmaceutical industry, specializing in cancer and vascular biology, immunology and bioanalysis in preclinical and clinical research. She has spent over 10 years developing and validating biomarker assays for biopharmaceuticals on a variety of instrumentation platforms to support clinical diagnostic research for therapeutic areas including oncology, inflammation, infectious and vascular diseases.